🔴 Sellas Life Sciences is trading 5.6% down as technology-sector weakness weighs on broader markets

Sellas Life Sciences is trading at $11.49, down 5.6%, as broader markets sell off amid technology-sector weakness and geopolitical tensions.

• The supplied market context shows the Nasdaq down 2.46% and the S&P 500 down 1.31%.
• No new company-specific catalyst explaining the October 22 decline was identified.
• A previously reported Pomerantz investigation concerns alleged delays in disclosing REGAL trial results; it was not a new October 22 announcement.